China guideline for the screening, early detection and early treatment of gastric cancer (2022, Beijing).
10.3760/cma.j.cn112152-20220617-00430
- VernacularTitle:中国胃癌筛查与早诊早治指南(2022，北京)
- Author:
Jie HE
1
;
Wan Qing CHEN
1
;
Zhao Shen LI
2
;
Ni LI
1
;
Jian Song REN
1
;
Jin Hui TIAN
3
;
Wen Jing TIAN
4
;
Fu Lan HU
5
;
Ji PENG
6
Author Information
1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. The First Affiliated Hos-pital of Naval Medical University, Shanghai 200433, China.
3. Evidence Based Medicine Center, Lanzhou University, Lanzhou 730000, China.
4. Public Health College of Harbin Medical University, Harbin 150081, China.
5. School of Public Health, Shenzhen University Health Science Center, Shenzhen 518037, China.
6. Shenzhen Centre for Chronic Disease Control, Shenzhen 518020, China.
- Collective Name:Expert Group of China Guideline for the Screening,Early Detection and Early Treatment of Gastric Cancer;;Working Group of China Guideline for the Screening, Early Detection and Early Treatment of Gastric Cancer
- Publication Type:Journal Article
- Keywords:
China;
Early diagnosis and early treatment;
Gastric neoplasms;
Guide-line;
Screening
- MeSH:
Beijing;
China/epidemiology*;
Early Detection of Cancer/methods*;
Humans;
Mass Screening;
Stomach Neoplasms/prevention & control*
- From:
Chinese Journal of Oncology
2022;44(7):634-666
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer (GC) is a major digestive tract malignancy in China, which seriously threatens the health of Chinese population. A large number of researches have demons-trated that screening, early detection and early treatment are effective in reducing the incidence and mortality of GC. The development of the guideline for GC screening, early detection and early treatment in line with epidemic characteristics of GC in China will greatly promote the homogeneity and standardization, and improve the effect of GC screening. This guideline was commissioned by the Bureau of Disease Control and Prevention of the National Health Commission. The National Cancer Center of China initiated and convened a working group comprising multidisciplinary experts. Following the World Health Organization Handbook for Guideline Development, this guideline combined the most up-to-date evidence of GC screening, China's national conditions, and practical experience in cancer screening. This guideline provided evidence-based recommendations with respect to the screening population, technology and procedure management, aiming to improve the effect of GC screening and provide scientific evidence for the GC prevention and control in China.
